Checkpoint Therapeutics, Inc. (CKPT)

Market Cap	142.26M
Revenue (ttm)	78,000
Net Income (ttm)	-42.47M
Shares Out	45.02M
EPS (ttm)	-1.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	933,012
Open	3.240
Previous Close	3.180
Day's Range	3.080 - 3.288
52-Week Range	1.360 - 3.620
Beta	1.30
Analysts	Strong Buy
Price Target	12.00 (+279.75%)
Earnings Date	Nov 11, 2024

About CKPT

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company’s lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 26, 2017
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: CKPT
• Website: https://checkpointtx.com

Financial Performance

In 2023, Checkpoint Therapeutics's revenue was $103,000, a decrease of -46.35% compared to the previous year's $192,000. Losses were -$51.85 million, -17.21% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for CKPT stock is "Strong Buy." The 12-month stock price forecast is $12.0, which is an increase of 279.75% from the latest price.

Price Target

$12.0

(279.75% upside)

Analyst Consensus: Strong Buy